{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:09:51Z","timestamp":1792634991514,"version":"4.5.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"13-14","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>\n                    Intravenous onasemnogene abeparvovec is approved for the treatment of spinal muscular atrophy in children &lt;\u20092 years. For later-onset patients, intrathecal onasemnogene abeparvovec may be advantageous over intravenous administration. Recently, microscopic dorsal root ganglion (DRG) changes were observed in nonhuman primates (NHPs) following intrathecal onasemnogene abeparvovec administration. To characterize these DRG findings, two NHP studies evaluating intrathecal onasemnogene abeparvovec administration were conducted: a 12-month study with a 6-week interim cohort and a 13-week study with a 2-week interim cohort. The latter investigated the potential impact of prednisolone or rituximab plus everolimus on DRG toxicity. An additional 6-month, single-dose, intravenous NHP study conducted in parallel evaluated onasemnogene abeparvovec safety (including DRG toxicity) with or without prednisolone coadministration. Intrathecal onasemnogene abeparvovec administration was well tolerated and not associated with clinical observations. Microscopic onasemnogene abeparvovec-related changes were observed in the DRG and trigeminal ganglion (TG) and included mononuclear cell inflammation and\/or neuronal degeneration, which was colocalized with high vector transcript expression at 6 weeks postdose. Incidence and severity of DRG changes were generally decreased after 52 weeks compared with 6 weeks postdose. Other onasemnogene abeparvovec-related microscopic findings of axonal degeneration, mononuclear cell infiltrates and\/or gliosis in the spinal cord, dorsal spinal nerve root\/spinal nerves, and\/or peripheral nerves were absent or found at decreased incidences and\/or severities after 52 weeks. DRG and\/or TG microscopic findings following intravenous onasemnogene abeparvovec dosing included minimal to slight neuronal degeneration and mononuclear cell inflammation at 6 weeks and 6 months postdose. Nervous system microscopic findings following intrathecal onasemnogene abeparvovec (\u22651.2\u2009\u00d7\u200910\n                    <jats:sup>13<\/jats:sup>\n                    vg\/animal) trended toward resolution after 52 weeks, supporting nonprogression of changes, including in the DRG. Onasemnogene abeparvovec-related DRG findings were not associated with electrophysiology changes and were not ameliorated by prednisolone or rituximab plus everolimus coadministration. The pathogenesis is possibly a consequence of increased vector genome transduction and\/or transgene expression.\n                  <\/jats:p>","DOI":"10.1089\/hum.2021.255","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T03:00:06Z","timestamp":1648177206000},"page":"740-756","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":54,"title":["Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys"],"prefix":"10.1177","volume":"33","author":[{"given":"Francis Fonyuy","family":"Tukov","sequence":"first","affiliation":[{"name":"Department of Preclinical Safety\/Translational Medicine, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Department of Discovery and Investigative Pathology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Milton","sequence":"additional","affiliation":[{"name":"Department of PK Sciences\u2014Gene Therapy TA, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Meseck","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Penraat","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Chand","sequence":"additional","affiliation":[{"name":"Novartis Gene Therapies, Inc., Bannockburn, Illinois, USA."},{"name":"Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Preclinical Safety, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2670"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.74"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70061-3"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01356-1"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24497"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1515"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24332"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.210"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000830"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq514"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.11.121"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.261"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01107-6"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.011"},{"key":"e_1_3_6_18_2","unstructured":"Hawk CT Leary SL Morris TH eds. Formulary for Laboratory Animals 3rd ed. Ames IA: Blackwell Publishing 2005."},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.113"},{"key":"e_1_3_6_20_2","unstructured":"FDA Pharmacology Review. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022334s000_PharmR.pdf (last accessed January7 2022)."},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313520351"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658038"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498250903189454"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq316"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.84"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-122"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200003150-00011"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198154"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.146"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.33"},{"key":"e_1_3_6_31_2","unstructured":"FDA Pharmacology Review. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000PharmR.pdf (last accessed January8 2022)."},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318761348"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14246-7"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23588"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/07367228509144581"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEUR.0000005596.88385.ec"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/860546"},{"key":"e_1_3_6_38_2","volume-title":"Toxicologic Pathology Nonclinical Safety Assessment, 1st ed","author":"Butt M","year":"2013","unstructured":"Butt M, , Sills R, , Bradley A. Nervous system. In: Sahota P, , Popp, Hardisty J, J, et al., eds. Toxicologic Pathology Nonclinical Safety Assessment, 1st ed. Boca Raton, FL: CRC Press\/Taylor & Francis Group, 2013:895\u2013930."},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.167"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.04.012"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.901390304"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.06.003"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020119"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2016.07.030"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00271"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-4-10"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.011"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005056"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2021.255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2021.255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2021.255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:10Z","timestamp":1777449370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2021.255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":48,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1089\/hum.2021.255"],"URL":"https:\/\/doi.org\/10.1089\/hum.2021.255","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}